OKYO Pharma Addresses Corneal Pain at the Renowned GPCRs-Targeted Drug Discovery Summit

Featuring in the prestigious GPCRs-Targeted Drug Discovery Summit, OKYO Pharma Limited is unveiling its progressive approaches in the treatment of neuropathic corneal pain and inflammatory eye diseases. With tens of thousands suffering worldwide, this condition characterized by severe, chronic eye discomfort is in desperate need of effective treatment options. OKYO Pharma CEO, Dr. Gary S. Jacob, will detail the development of urcosimod, the company’s chief clinical drug candidate for the treatment of this debilitating condition. The presentation is set for the 4th annual summit taking place in Boston, Massachusetts on May 22, 2025. Neuropathic Corneal Pain (NCP) has its roots in nerve damage to the cornea, compounded by inflammation. There’s currently no approved therapy for this condition, leaving patients to navigate a maze of off-label treatments with limited success. However, all that could change with urcosimod (formerly named OK-101). Urcosimod is recognised as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor. This presents an innovative opportunity to tackle dry eye disease, through its anti-inflammatory and pain-reducing properties. The drug has shown promising results in Phase 2 trials, offering hope for patients, and demonstrating the commitment and innovation that OKYO Pharma is bringing to the medical community. OKYO Pharma continues to advance in the industry with their focus on the discovery and development of novel molecules for treating ocular diseases, aiming to lead the charge in the battle against neuropathic corneal pain.